Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: When JnJ Speaks, Others Copy

This article was originally published in Scrip

Executive Summary

In David Thomas' 2011 novel Blood Relative, a husband tries to recreate his wife's life in the heart of the former German Democratic Republic as a time when the influence of the socialist state was absolute. In a similar way, but in the home of capitalism, the world's largest healthcare company Johnson & Johnson (J&J) reported its third-quarter earnings last week and its methods to massage the news quickly influenced announcements of much smaller companies.

You may also be interested in...



Stockwatch: Details Differ Between Pfizer And AstraZeneca's Second-Quarter Earnings Reports

Investors in pharmaceutical companies appreciate details such as sales force dynamics, price-volume relationships and channel-stocking effects. Their absence can make investors wary.

Stockwatch: Full-Year 2020 Guidance Separates Novartis And Roche

Pandemic-related clinic closures and safety issues forced Novartis to trim its guidance slightly. But Roche, faced with more severe pandemic and biosimilar pressures, left January’s guidance unchanged.

Stockwatch: The Not-As-Bad-As-Expected Opera Of Johnson & Johnson’s Q2 Earnings

With something for everyone in Johnson & Johnson’s second-quarter earnings report, a nudge upwards for full-year guidance could not disguise the jump down from January’s pre-pandemic expectations.

Topics

Related Companies

UsernamePublicRestriction

Register

LL030495

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel